<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260438</url>
  </required_header>
  <id_info>
    <org_study_id>A98_01BE1922P</org_study_id>
    <nct_id>NCT04260438</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Fed, Single Dose, Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, randomized, fed, single dose, crossover study to evaluate the
      pharmacokinetics, safety and tolerability of CKD-393 in healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To healthy subjects of twenty-four (24), following treatments are administered dosing in each
      period and wash-out period is a minimum of 7 days.

      Reference drug: 1) CKD-501 0.5mg 2) D759 3) D150 Test drug: 1) CKD-393 0.5/100/1000mg
      formulation Ⅰ Tab. 2) CKD-393 0.5/100/1000mg formulation Ⅱ Tab.

      Pharmacokinetic blood samples are collected up to 48hrs. The pharmacokinetic characteristics
      and safety are assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 27, 2020</start_date>
  <completion_date type="Anticipated">April 22, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 13, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of CKD-501, D759, D150, CKD-393</measure>
    <time_frame>Time Frame: 0 hour ~ 48 hours</time_frame>
    <description>Area under the CKD-501/D759/D150/CKD-393 concentration in blood-time curve from zero to final</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of CKD-501, D759, D150, CKD-393</measure>
    <time_frame>Time Frame: 0 hour ~ 48 hours</time_frame>
    <description>The maximum CKD-501/D759/D150/CKD-393 concentration in blood sampling time t</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A
Period 2: Treatment B
Period 3: Treatment C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment A
Period 2: Treatment C
Period 3: Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B
Period 2: Treatment A
Period 3: Treatment C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment B
Period 2: Treatment C
Period 3: Treatment A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C
Period 2: Treatment A
Period 3: Treatment B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Treatment C
Period 2: Treatment B
Period 3: Treatment A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-501 0.5mg Tab. 1T, D759 100mg Tab. 1T and D150 1000mg Tab. 1T</intervention_name>
    <description>single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Treatment A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-393 0.5/100/1000mg formulation 1 Tab. 1T</intervention_name>
    <description>single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Treatment B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-393 0.5/100/1000mg formulation 2 Tab. 1T</intervention_name>
    <description>single oral administration under fed condition</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <other_name>Treatment C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers, aged between ≥ 19 and ≤ 55 years old at the time of
             screening.

          2. Weight ≥ 50kg, with calculated body mass index (BMI) of ≥ 18.5 and ≤ 29.9 kg/m2

             * BMI = Weight(kg)/ Height(m)2

          3. Subject who consents to use at least two clinically effective birth controls for at
             least 1 month following the last dose.

          4. Subject is informed of the investigational nature of this study and voluntarily agrees
             to participate in this study and comply with the relevant instructions in written.

        Exclusion Criteria:

          1. History or presence of clinically significant and sever active cardiovascular,
             respiratory, hepatobiliary, renal, endocrine, hematological, gastrointestinal,
             neurologic, immune, dermatologic or psychiatric disorder.

          2. With symptoms indicating acute illness within 28 days prior to the first
             Investigational Product (IP) administration.

          3. Any medical history that may affect drug absorption, distribution, metabolism and
             excretion.

          4. Individuals who had history of hypersensitivity to follow drugs, derivative drugs or
             others drugs(aspirin and antibiotics etc.) or had history of drug abuse

               -  Thiazolidinedione

               -  DPP-4 inhibitor

               -  Metformin

          5. Any clinically significant chronic medical illness.

          6. Any genetic disease including galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption.

          7. Individuals with one of the following laboratory test results in screening

               -  AST, ALT &gt; UNL (upper normal limit) x 3

               -  fasting glucose &lt; 70 mg/dL or &gt; 125 mg/dL

               -  Creatinine clearance ≤ 80 mL/min

               -  In ECG result, QTc &gt; 450 msec

               -  hCG(+) (only women)

          8. Individuals who had positive test results at HBs Ag, anti-HCV Ab, anti-HIV Ab, VDRL.

          9. Use of any prescription drugs within 14 days prior to study drug administration.

         10. Use of over-the-counter medications and herbal preparations within 7 days prior to
             study drug administration.

         11. History of any clinically significant allergic reaction (However, mild allergic
             rhinitis or allergic dermatitis which do not required medication may be allowed).

         12. Individuals who cannot eat standard meal provided from clinical trial center.

         13. Donation of blood within 60 days prior to study drug administration or apheresis
             within 20 days prior to the first IP administration.

         14. Individuals who had received a blood transfusion within 30 days prior to study drug
             administration.

         15. Exposure to any investigational drug within 6 months prior to the first IP
             administration.

         16. Individuals taking any drugs inducing or inhibiting drug metabolizing enzymes
             including barbiturates within 30 days prior to the first IP administration.

         17. Individuals who had consumed grapefruit juice &gt; 5cups/day or caffeine &gt; 5cups/day
             within 30 days prior to the first IP administration or who cannot stopping consume
             grapefruit juice or caffeine during clinical study.

         18. Individuals who had drinking (alcohol &gt; 30 g/day) within 30 days prior to the first IP
             administration or who cannot stopping drink.

         19. Heavy smoking (more than 10 cigarettes/day) within 30 days prior to screening or who
             cannot quit smoking during clinical study.

         20. Pregnant or women who may be pregnant

         21. Subjects having been deemed inappropriate for the trial as determined by the
             investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji-Young Park</last_name>
    <phone>+82-2-920-6288</phone>
    <email>jypark21@korea.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kyoung-Ah Kim</last_name>
    <email>kakim920@kmumc.or.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Ji-Young Park</last_name>
      <phone>+82-2-920-6288</phone>
      <email>jypark21@korea.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Kyoung-Ah Kim</last_name>
      <email>kakim920@kmumc.or.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

